These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 28581634)

  • 81. Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre-and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir.
    McPhee F; Hernandez D; Zhou N; Ueland J; Yu F; Vellucci V; Huang X; Wang X; Ishikawa H; Karino Y; Kumada H
    Antivir Ther; 2018; 23(1):53-66. PubMed ID: 28594332
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Is elimination of hepatitis C from the UK by 2030 a realistic goal?
    Gelson W; Alexander G
    Br Med Bull; 2017 Sep; 123(1):59-67. PubMed ID: 28605444
    [TBL] [Abstract][Full Text] [Related]  

  • 83. High hepatitis C cure rates among black and nonblack human immunodeficiency virus-infected adults in an urban center.
    Falade-Nwulia O; Sutcliffe C; Moon J; Chander G; Wansom T; Keruly J; Katzianer J; Nathanson A; Marks J; Mehta S; Thomas D; Moore R; Sulkowski M
    Hepatology; 2017 Nov; 66(5):1402-1412. PubMed ID: 28608973
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015.
    Spradling PR; Xing J; Rupp LB; Moorman AC; Gordon SC; Lu M; Teshale EH; Boscarino JA; Schmidt MA; Daida YG; Holmberg SD;
    J Clin Gastroenterol; 2018 Aug; 52(7):641-647. PubMed ID: 28590325
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
    Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
    Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Mixed cryoglobulinaemia: An important but frequently unrecognized and underestimated HCV-related condition in the real life practice.
    Kondili LA; Vella S; Zignego AL;
    Liver Int; 2018 Jan; 38(1):183. PubMed ID: 28599083
    [No Abstract]   [Full Text] [Related]  

  • 87. Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study.
    Salcedo M; Prieto M; Castells L; Pascasio JM; Montero Alvarez JL; Fernández I; Sánchez-Antolín G; González-Diéguez L; García-Gonzalez M; Otero A; Lorente S; Espinosa MD; Testillano M; González A; Castellote J; Casafont F; Londoño MC; Pons JA; Molina Pérez E; Cuervas-Mons V; Pascual S; Herrero JI; Narváez I; Vinaixa C; Llaneras J; Sousa JM; Bañares R
    Transpl Int; 2017 Oct; 30(10):1041-1050. PubMed ID: 28608619
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Safety Profile of Telaprevir-Based Triple Therapy in Elderly Patients: A Real-World Retrospective Cohort Study.
    Akutagawa M; Ide K; Kawasaki Y; Yamanaka M; Iketani R; Yamada H; Masaki N
    Biol Pharm Bull; 2017 Sep; 40(9):1525-1529. PubMed ID: 28603159
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Decreased pro-inflammatory immune responses during recurrent acute HCV infections in HIV co-infected patients.
    Hullegie SJ; Arends JEA; Groothuismink ZMA; Pas SD; Rijnders BJA; Boonstra A; Claassen MAA
    J Gen Virol; 2017 Jun; 98(6):1294-1298. PubMed ID: 28597817
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Low frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study.
    Palladino C; Sánchez-Carrillo M; Mate-Cano I; Vázquez-Morón S; Jimenez-Sousa MÁ; Gutiérrez-Rivas M; Resino S; Briz V
    Sci Rep; 2017 Jun; 7(1):2892. PubMed ID: 28588311
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Increased warfarin requirements in a patient with chronic hepatitis C infection receiving sofosbuvir and ribavirin.
    Peterson D; Van Ermen A
    Am J Health Syst Pharm; 2017 Jun; 74(12):888-892. PubMed ID: 28596225
    [TBL] [Abstract][Full Text] [Related]  

  • 92. 2'-Chloro,2'-fluoro Ribonucleotide Prodrugs with Potent Pan-genotypic Activity against Hepatitis C Virus Replication in Culture.
    Zhou S; Mahmoud S; Liu P; Zhou L; Ehteshami M; Bassit L; Tao S; Domaoal RA; Sari O; Schutter C; Amiralaei S; Khalil A; Ollinger Russell O; McBrayer T; Whitaker T; Abou-Taleb N; Amblard F; Coats SJ; Schinazi RF
    J Med Chem; 2017 Jul; 60(13):5424-5437. PubMed ID: 28595015
    [TBL] [Abstract][Full Text] [Related]  

  • 93. NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains.
    Benzine T; Brandt R; Lovell WC; Yamane D; Neddermann P; De Francesco R; Lemon SM; Perelson AS; Ke R; McGivern DR
    PLoS Pathog; 2017 Jun; 13(6):e1006343. PubMed ID: 28594932
    [TBL] [Abstract][Full Text] [Related]  

  • 94. HIV and hepatitis C treatment uptake among people who use drugs participating in the Amsterdam Cohort Studies, 1985-2015.
    van Santen DK; van der Helm JJ; Lindenburg K; Schim van der Loeff M; Prins M
    Int J Drug Policy; 2017 Sep; 47():95-101. PubMed ID: 28606392
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Clinical and Pathological Risk Factors Associated with Liver Fibrosis and Steatosis in African-Americans with Chronic Hepatitis C.
    Afsari A; Lee E; Shokrani B; Boortalary T; Sherif ZA; Nouraie M; Laiyemo AO; Alkhalloufi K; Brim H; Ashktorab H
    Dig Dis Sci; 2017 Aug; 62(8):2159-2165. PubMed ID: 28612194
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals.
    Samur S; Kues B; Ayer T; Roberts MS; Kanwal F; Hur C; Donnell DMS; Chung RT; Chhatwal J
    Clin Gastroenterol Hepatol; 2018 Jan; 16(1):115-122.e10. PubMed ID: 28634131
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Behavioural, not biological, factors drive the HCV epidemic among HIV-positive MSM: HCV and HIV modelling analysis including HCV treatment-as-prevention impact.
    MacGregor L; Martin NK; Mukandavire C; Hickson F; Weatherburn P; Hickman M; Vickerman P
    Int J Epidemiol; 2017 Oct; 46(5):1582-1592. PubMed ID: 28605503
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Association of IL-12 B Gene Polymorphism with Staging of Liver Disease in Chronic HCV Patients.
    Elwan N; Amr K; Elyamany S; Elkhalawany W; Soliman S; Ziada M; Abd-Elsalam S
    Infect Disord Drug Targets; 2018; 18(2):122-128. PubMed ID: 28595541
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants.
    Matthew AN; Zephyr J; Hill CJ; Jahangir M; Newton A; Petropoulos CJ; Huang W; Kurt-Yilmaz N; Schiffer CA; Ali A
    J Med Chem; 2017 Jul; 60(13):5699-5716. PubMed ID: 28594175
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Development of a web-based application and multicountry analysis framework for assessing interdicted infections and cost-utility of screening donated blood for HIV, HCV and HBV.
    Custer B; Janssen MP; Hubben G; Vermeulen M; van Hulst M
    Vox Sang; 2017 Aug; 112(6):526-534. PubMed ID: 28597489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.